Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Código QR

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Cüneyt Ünsal,1 Yakup Albayrak,1 Neslihan Albayrak,2 Murat Kuloğlu,3 Kenji Hashimoto41Department of Psychiatry, Namik Kemal University School of Medicine, Tekirdag, Turkey; 2Department of Cardiology, Kirklareli State Hospital, Kirklareli, Turkey; 3Department of Psychiatry, Akdeniz U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	&Uuml;nsal C, Albayrak Y, Albayrak N, Kuloğlu M, Hashimoto K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9c6e136560ef477ca80f306468e212b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Increased serum levels of apoptosis in deficit syndrome schizophrenia patients: a preliminary study
por: Beyazyüz M, et al.
Publicado: (2016)

Reduced serum brain-derived neurotrophic factor in patients with first onset vitiligo
por: Yanik ME, et al.
Publicado: (2014)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
por: Yang F, et al.
Publicado: (2018)

Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study
por: Gabriel A
Publicado: (2013)

Decreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome
por: Akyol ES, et al.
Publicado: (2015)

The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens J
Publicado: (2011)

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili N
Publicado: (2012)

Paraoxonase-1 and Early-Life Environmental Exposures
por: Judit Marsillach, et al.
Publicado: (2016)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Takahashi M, et al.
Publicado: (2012)

Suppression of inflammatory arthritis in human serum paraoxonase 1 transgenic mice
por: Christina Charles-Schoeman, et al.
Publicado: (2020)

Frontocingulate Dysfunction Is Associated with Depression and Decreased Serum PON1 in Methamphetamine-Dependent Patients
por: Ghavidel N, et al.
Publicado: (2020)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri H, et al.
Publicado: (2018)

Does participation in a weight control program also improve clinical and functional outcomes for Chinese patients with schizophrenia treated with olanzapine?
por: Montgomery W, et al.
Publicado: (2014)

Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients
por: Yoshimura B, et al.
Publicado: (2013)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
por: Citrome L, et al.
Publicado: (2019)

Detection of subclinical atherosclerosis and diastolic dysfunction in patients with schizophrenia
por: &Uuml;nsal C, et al.
Publicado: (2013)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Rosaria Di Lorenzo, et al.
Publicado: (2010)

Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus
por: Kiss Alexander, et al.
Publicado: (2020)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
por: Adel Gabriel
Publicado: (2010)

Quetiapine monotherapy for bipolar depression
por: Michael E Thase
Publicado: (2008)

Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia
por: Albayarak Y, et al.
Publicado: (2015)

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
por: Strzelecki D, et al.
Publicado: (2015)

The Increase in Paraoxonase 1 Is Associated With Decrease in Left Ventricular Volume in Kidney Transplant Recipients
por: Philip W. Connelly, et al.
Publicado: (2021)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki H, et al.
Publicado: (2013)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao K, et al.
Publicado: (2013)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum H, et al.
Publicado: (2014)

Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics
por: Takahiko Nagamine
Publicado: (2008)

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
por: Ann E Maloney, et al.
Publicado: (2010)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
por: Okazaki K, et al.
Publicado: (2017)

Paraoxonase 1 gene variants concerning cardiovascular mortality in conventional cigarette smokers and non-smokers treated with hemodialysis
por: Alicja E. Grzegorzewska, et al.
Publicado: (2021)

ESSENTIAL THROMBOCYTOSIS IN CHILDREN
por: Canan ALBAYRAK, et al.
Publicado: (2021)

Role of extended release quetiapine in the management of bipolar disorders
por: Rayan K Al Jurdi, et al.
Publicado: (2010)

Investigation of PON1 activity and MDA levels in patients with epilepsy not receiving antiepileptic treatment
por: Dönmezdil N, et al.
Publicado: (2016)

An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia
por: Giorgio L Colombo, et al.
Publicado: (2008)

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri H, et al.
Publicado: (2018)

Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum
por: Kiss Alexander, et al.
Publicado: (2019)

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
por: Endicott J, et al.
Publicado: (2012)

A review of quetiapine in combination with antidepressant therapy in patients with depression
por: Ella J Daly, et al.
Publicado: (2007)

Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression
por: Laura Gedge, et al.
Publicado: (2010)

Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients
por: Alicja E. Grzegorzewska, et al.
Publicado: (2021)